Role of fesoterodine in the treatment of overactive bladder. - Wikidata - wikimedia - TriplyDB

Role of fesoterodine in the treatment of overactive bladder.

Role of fesoterodine in the treatment of overactive bladder.

http://www.wikidata.org/entity/Q37283542

about

Expert Opinion on Three Clinical Cases with a Common Urgent Problem: Urge Urinary Incontinence

P2860

Q58551871-30865818-05C0-4FE7-B22F-3B27AA22D77E

P2860

Role of fesoterodine in the treatment of overactive bladder.

http://www.wikidata.org/entity/Q37283542

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 December 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Role of fesoterodine in the treatment of overactive bladder.

@en

Role of fesoterodine in the treatment of overactive bladder.

@nl

type

label

Role of fesoterodine in the treatment of overactive bladder.

@en

Role of fesoterodine in the treatment of overactive bladder.

@nl

prefLabel

Role of fesoterodine in the treatment of overactive bladder.

@en

Role of fesoterodine in the treatment of overactive bladder.

@nl

P1433

Q37283542-F3425582-55AD-4334-9996-ED1B88B9BD03

P1476

Q37283542-F7503F72-53B1-48A6-8963-B87544EDAC8A

P2093

Q37283542-51606408-A2CC-40F0-B224-1C19B396179B

P2860

Q37283542-02365FAE-D466-4993-BACB-6FB87FA35552

Q37283542-03E69EC2-CE1E-4EDE-9CE6-02B3F818FF85

Q37283542-0545EE40-6654-4B7F-A139-4C22FA1D8442

Q37283542-09C71638-11B3-425F-BCBB-5C754F577381

Q37283542-0D1C6844-EA91-4BF0-8B67-10A86DC341C8

Q37283542-179CA742-291D-42D1-BD49-E7A5D7AEC9FC

Q37283542-18D8E731-C6A0-4614-AFAA-963EA12CA300

Q37283542-1D7BB8D1-FD98-4CBA-9DC4-28F9AE2123F1

Q37283542-1E11516F-6124-4252-8FFB-FEEB08BF154D

Q37283542-267BE09E-C249-443A-A4F9-758530570E3B

P304

Q37283542-C974B6F0-C2F9-4DED-A646-F56DBEBF938A

P31

Q37283542-A1A30E56-4FB6-4B42-8B25-FA6DCDD7B0EA

P356

Q37283542-349B8017-5C79-46C9-A2A5-EFB5A28A11F9

P478

Q37283542-CE348CE9-EAD4-4068-A019-CB9B2CF782F5

P577

Q37283542-54FB3A9A-94AC-45C2-AD88-8E8446F685D9

P698

Q37283542-A2A9EDDD-6BF6-440C-9993-B52A3C4A054C

P932

Q37283542-726B3BDF-DE17-449D-BB08-39E32F88230A

P356

P1433

Open Access Journal of Urology

P1476

Role of fesoterodine in the treatment of overactive bladder.

@en

P2093

Kylie J Mansfield

http://www.w3.org/2001/XMLSchema#string

P2860

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype

Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data.

Impact of fesoterodine on quality of life: pooled data from two randomized trials.

Molecular basis of ethnic differences in drug disposition and response.

Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor.

M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.

Prevalence and burden of overactive bladder in the United States.

Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.

Muscarinic receptors in the bladder: from basic research to therapeutics.

P304

1-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/RRU.S5171

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24198608

http://www.w3.org/2001/XMLSchema#string

P932

3818872

http://www.w3.org/2001/XMLSchema#string